Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Growth Rebounds But Pharma Starts Cutting Prices

Executive Summary

The second quarter has been a period of stabilization for multinational drug makers in China, where the challenges of cost-cutting and a national policy to encourage domestic generics remain. Big pharmas including Novartis and Roche are voluntarily reduce prices for major products, to help them compete, reflecting a new willingness to improve patient access in the world's second-largest pharma market.

You may also be interested in...

What’s Separating The Growers And No-Growers In China?

Multinational pharma firms have had a widely varied quarter in China, with some clear winners emerging with double-digit growth while others are still in the doldrums. What are the factors behind the figures?

Diabetes Delivers China Strength For Merck

Merck & Co reported continued good growth in China in the second quarter, helped in large part by its diabetes franchise, and the company is looking to further strengthen its presence in this market through disease awareness efforts and a major recently inaugurated R&D center.

Pfizer Sees Bright Long Term Biosimilar Future In China

Despite shorter term general cost pressures and the time needed for approval reviews, Pfizer sees a strong future for its biosimilar operations in China, as it recorded a solid second quarter performance for its traditional franchises and unveiled a series of new health alliances in this key emerging market.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts